Iksuda Plans IKS03 Lymphoma Data at ASH
Early phase 1 results show 53% objective response rate in advanced B-cell non-Hodgkin lymphoma, with updated data due at the 2026 ASH meeting.
Updated on Nov. 7, 2026 in Cancer
Iksuda Therapeutics reported preliminary phase 1 data for IKS03, a CD19-targeting antibody drug conjugate, in patients with advanced B-cell non-Hodgkin lymphoma. Updated results are scheduled for presentation at the 68th American Society of Haematology Annual Meeting in December 2026.
Why it matters
Early responses in a heavily pretreated lymphoma population suggest IKS03 may warrant further study in this setting. Dose escalation is still ongoing, so the safety profile and optimal dose remain unsettled.
The preliminary phase 1 study enrolled 21 patients across five dose levels up to 3.1 mg/m2, with 17 evaluable for efficacy and a 53% objective response rate. Because dose escalation is ongoing and no maximum tolerated dose has been identified, the durability and optimal dose of these responses remain unknown.
The players
Iksuda Therapeutics
Iksuda Therapeutics is a biotechnology company developing antibody drug conjugates for cancer treatment.
American Society of Haematology
The American Society of Haematology is a professional organization that hosts one of the world's largest annual meetings on blood disorders and cancers.
The details
IKS03 is a CD19-targeting antibody drug conjugate that delivers a tumour-activated prodrug pyrrolobenzodiazepine payload. The first-in-human multicentre study uses a 3+3 dose escalation design, with one Grade 4 neutropenia dose-limiting toxicity and no Grade 5 events or treatment-related serious adverse events reported.
Timeline
July 8, 2026: Data cutoff for treated patient counts and dosing.
December 12 to 15, 2026: Updated results to be presented at the 68th ASH Annual Meeting in New Orleans.
Health Landscape
IKS03 extends the CD19-directed antibody drug conjugate approach already used in B-cell lymphoma by pairing the antibody with a tumour-activated prodrug payload. Its early response rate will be judged against existing CD19-targeted conjugates once larger dose-expansion data are available.
For people with relapsed or refractory B-cell lymphoma, IKS03 is still an investigational treatment available only through clinical trials. Patients considering participation should discuss the trial's eligibility criteria and known side effects with their oncologist.
The takeaway
Early IKS03 data show encouraging responses in advanced lymphoma, but the trial is still dose-finding and results are preliminary. Readers should watch for the fuller safety and efficacy data expected at the December 2026 meeting.
What happens next
Updated IKS03 results are scheduled for presentation at the 68th ASH Annual Meeting in New Orleans from December 12 to 15, 2026, and around 140 patients are expected to be enrolled across the study.
Further reading
Explore more on Cancer research and treatment advances.
More information
Details of the study are listed in the IKS03 phase 1 clinical trial registration.
Source note: This article includes information reported by Pharmabiz.
